Apixiban more effective than enoxaparin for prevention of postoperative thromboembolism
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): A randomised double-blind trialLancet. 2010 Mar 6;375(9717):807-15.
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
3057 patients scheduled for an elective unilateral or same-day bilateral total knee replacement were randomized to the drug used in prevention of venous thromboembolism, either oral apixiban or subcutaneous enoxaparin. 60 days after the final dose apixiban when compared to enoxaparin was found to be more effective in preventing thrombosis events, had lesser bleeding risks, and had the convenience ...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE